Scientific Areas of Integrated Review Groups (IRGs)
For a listing of the Scientific Review Administrator and membership roster for each study section, click on the study section roster under the study section name within the IRG listed below or go to the study section index (study sections listed alphabetically) and click on the specified roster next to the name of the study section.
Last updated on 26th October, 2004.
|
Referral & Review |
Oncological
Sciences IRG [ONC]
|
The Oncological Sciences [ONC] Integrated Review Group (IRG) will consider applications involving basic, translational, and clinical investigations that encompass cancer prevention, initiation, promotion, progression, diagnosis and treatment. Specifically, the ONC IRG reviews research grant applications related to chemical carcinogenesis, cancer genetics, nutritional carcinogenesis, radiation effects, and tumor biology; mechanism of action of cancer therapeutic agents in both in vitro and in vivo model systems; development and evaluation of experimental therapies of neoplastic diseases, translation of basic research to clinical practice; development or optimization of treatment modalities; chemoprevention; and development of biomarkers/signatures for tumor detection and diagnosis.
The following Study Sections are included within the ONC IRG:
Cancer Etiology Study Section [CE] Cancer Genetics Study Section [CG] Cancer Molecular Pathobiology [CAMP] Tumor Cell Biology Study Section [TCB] Tumor Microenvironment Study Section [TME] Tumor Progression and Metastasis Study Section [TPM] Chemo/Dietary Prevention Study Section [CDP] Cancer Biomarkers Study Section [CBSS] Radiation Therap Cancer Immunopathology and Immunotherapy Study Section [CII] Drug Discovery and Molecular Pharmacology Study Section [DMP] Developmental Therapeutics Study Section [DT] Clinical Oncology Study Section [CONC] Oncological
Sciences Fellowship Study Section [F09]
Cancer
Etiology Study Section [CE] The Cancer Etiology Study Section reviews grant
applications related to the causal agents, processes, and cells involved in
tumor pathogenesis. The areas included within CE involve the conversion
of normal cells to cancer cells, including neoplastic lesions and events
leading to the tumor becoming invasive. Organ-specific oncogenesis is
included in this study section. Tools often utilized in these studies
include: animal models (e.g., knockouts and transgenics), in vitro models
(e.g., cell lines and explant cultures), functional imaging (e.g.,
Fluorescence Resonance Energy Transfer- FRET), and structural biology. Specific
areas covered by CE include: ·
Signal transduction: including
growth factors, cytokines, receptors, post-translational modifications and
intracellular mediators (such as arachidonic acid and transcription factors) ·
Protein degradation and
stability (including ubiquitination) ·
Gene regulation: including
transcription factors, RNA stability and processing, as they contribute to
oncogenesis ·
Immortalization and senescence:
including the action of telomerase ·
Differentiation/transdifferentiation
in oncogenesis ·
Cell cycle/checkpoints (as
related to initiation events) ·
Chemical- and radiation-induced
mutagenesis ·
Processes involved in chemical
carcinogenesis leading to damage to the genome (including DNA adduction,
xenobiotic metabolism, and identification of causal agents) ·
Viral carcinogenesis ·
Metabolism: including metabolism
of endogenous compounds ·
Stress responses: including
oxidative stress and reactive oxygen species CE has the
following shared interests within the ONC IRG: ·
With CG regarding hereditary tumors, gene polymorphisms and
pathogen-associated tumors. In general genetic studies would be
assigned to CG; if emphasis is on the etiology of disease it would be
assigned to CE. ·
With CAMP in signal transduction, protein degradation, cell
cycle checkpoint, etc: In general, CAMP reviews studies related to
participation in oncogenesis while CE is more involved in understanding
fundamental processes. ·
With CBSS regarding discovery and evaluation of genetic and
epigenetic abnormalities in tumors that may serve as clinical biomarkers for
disease prognosis or predicting response to therapy. When the focus is
on identification of markers for clinical applications, the proposal should
be assigned to CBSS; when the focus is on understanding the disease process the
applications should be assigned to CE. ·
With RTB regarding oxidative stress, reactive oxygen
species, cell cycle/checkpoints, and signal transduction: studies related to
modulation of radiation response or mechanisms of action should be assigned
to RTB; broader studies should be assigned to CE. ·
With DMP as it relates to processes and targets involved in
oncogenesis. Studies relating to drug discovery and development should be
assigned to DMP, more basic studies of cancer processes and targets should be
assigned to CE. ·
With DT in studies of signal transduction, cell cycle
regulation, apoptosis, and differentiation. Therapeutically oriented
studies, should be assigned to DT, more basic studies should be assigned to
CE. CE has the
following shared interests outside the ONC IRG: ·
With the Biological
Chemistry and Macromolecular Biophysics [BCMB] IRG: In general, molecular studies not focused on the
etiology of cancer would be assigned to BCMB; if the study is focused on the
etiology of cancer, it would be assigned to CE. ·
With the Genes, Genomes
and Genetics [GGG] IRG: In general, gene
function studies not uniquely relevant to the etiology of cancer would be
assigned to GGG; studies focused on the etiology of cancer would be assigned
to CE. ·
With the Cell Biology [CB]
IRG: In general, if the
findings could also be relevant to another area of biomedical research, the
application would be assigned to MACFI; cell studies uniquely relevant to the
etiology of cancer would be assigned to CE. ·
With the Health of the
Population [HOP] IRG: In general, if an epidemiological approach is
central to the study, review would be in HOP; studies of cancer etiology
would be assigned to CE. ·
With the Infectious
Diseases and Microbiology [IDM] IRG: In general, studies of
infections as a trigger of cancer could be assigned to CE or IDM depending on
the emphasis of the study; studies of the etiology of cancer would be
assigned to CE. ·
With the AIDS and Related
Research [AARR] IRG: In general, studies of the etiology of
HIV/AIDS-associated cancers would be assigned to AARR. ·
With the Hematology [HEME]
IRG: In general, applications that focus on normal
development or the etiology of abnormal development of hematological cells
(including red blood cell malignancies) and other pathologies would be
assigned to HEME; applications that are exclusively focused on the etiology
of leukemia or lymphoma would be assigned to CE. ·
With the Endocrinology,
Metabolism, Nutrition and Reproductive Sciences [EMNR] IRG: In general, studies of pre-neoplastic, dysplastic
and hyperplastic disorders of the reproductive organs would be assigned to EMNR.
Studies of the etiology of endometrial hyperplasia; trophoblast neoplasia;
germ cell tumors; pituitary adenomas; as well as thyroid, parathyroid, and
adrenal tumors would be assigned to EMNR; studies of the etiology of tumors
of reproductive organs would be assigned to CE. ·
With the Musculoskeletal,
Oral, and Skin Sciences [MOSS] IRG: In general, studies of
pre-neoplastic skin disorders would be assigned to MOSS; studies of the
etiology of oral, head and neck cancer, and bone tumors would be assigned to
CE. ·
With the Digestive
Sciences [DIG] IRG: In general, studies of pre-neoplastic conditions as
a consequence of chronic esophageal or gastrointestinal infection or
inflammation, and pre-neoplastic conditions of the liver or pancreas would be
assigned to DIG. ·
With the Renal and
Urological Sciences [RUS] IRG: In general, studies related to differentiation in
the context of urinary tract or kidney development or other diseases, or
studies focused on benign processes in the kidney, urinary tract, or male
genital system would be assigned to RUS; studies of early events in malignant
transformation focused on the neoplastic process would be assigned to CE. ·
With the Brain Disorders
and Clinical Neuroscience [BDCN] IRG: In general, studies of
malignant transformation and progression in the context of specific brain
tumors would be assigned to BDCN; studies of malignant transformation or
progression more broadly applicable to neoplastic processes would be assigned
to CE. Cancer
Genetics Study Section [CG] The Cancer Genetics [CG] Study Section reviews grant
applications related to the causal agents and target genes involved in tumor
pathogenesis. Organ-specific carcinogenesis is included in this study
section. Studies using both mammalian and non-mammalian models are
included. Specific
areas covered by CG include: ·
Oncogene discovery, genomics,
and proteomics (including molecular and biochemical profiling) ·
Positional cloning ·
Animal models for gene discovery ·
Cancer genetics: including
hereditary and somatic DNA alterations, allelic imbalance/LOH ·
Epigenetics: including DNA
methylation and imprinting ·
Metabolizing enzyme polymorphisms and
mutations ·
Genomic
instability: including microsatellite and chromosomal
instability ·
Susceptibility/modifier genes that modify
susceptibility to cancer without allelic loss including low penetrance
genes identified in human and animal models CG has the
following shared interests within the ONC IRG: ·
With CE in development of early
biomarkers and in organ-specific carcinogenesis. If emphasis is in
the etiology of disease it should be assigned to CE, in general other
genetic studies should be assigned to CG. ·
With TPM as it relates to tumor
progression. If genetic control of tumor progression is the central
focus, the application should be assigned to TPM. ·
With CBSS regarding discovery and
evaluation of genetic and epigenetic abnormalities in tumors that may
serve as clinical biomarkers. When the focus is on identification of
biomarkers for clinical applications, the proposal should be assigned to
CBSS; when the focus is on understanding the disease process the
applications should be assigned to CG. ·
With RTB in genomic instability: If
the instability relates to radiation effects the application should be
assigned to RTB, other examples of genomic instability should be assigned
to CG. ·
With DMP in studies of processes and
targets involved in oncogenesis. Pharmacological studies should be
assigned to DMP while studies focused on cancer genetics would be assigned
to CG. CG has the
following shared interests outside the ONC IRG: ·
With the Genes, Genomes and
Genetics [GGG] IRG: In general, if the
findings could also be relevant to another area of biomedical research,
the study would be assigned to GGG; fundamental genetic and gene function
studies uniquely relevant to oncology would be assigned to CG. ·
With the Hematology [HEME]
IRG: In general studies of the genetics of lymphoma and
leukemia would be assigned to CG. ·
With the Endocrinology,
Metabolism, Nutrition and Reproductive Sciences [EMNR]
IRG: In general, studies of the
genetics of endometrial hyperplasia; trophoblast neoplasia; germ cell
tumors; pituitary adenomas; as well as thyroid, parathyroid, and adrenal
tumors would be assigned to EMNR; studies of genetics of reproductive
organ tumors would be assigned to CG. ·
With the Digestive Sciences
[DIG] IRG: In general, genetic studies
of the pre-neoplastic stages of GI, liver, or pancreas would be assigned
to DIG; genetic studies of GI, liver, or pancreatic cancers would be
assigned to CG. ·
With the Renal and Urological
Sciences [RUS] IRG: In general, genetic
studies focused on the malignant transformation in the context of urinary
tract or kidney development or other diseases; or studies focused on
benign processes in the kidney, urinary tract, or male genital system
would be assigned to RUS; genetic studies of malignant transformation
focused on the neoplastic process would be assigned to CG. Studies
of genes and their products that are involved in both neoplastic and
normal developmental processes (e.g., WT1 and VHL) would be assigned to
RUS or CG, depending on the focus of the study. Cancer Molecular Pathobiology Study Section
[CAMP] The Cancer Molecular Pathobiology [CAMP] Study
Section reviews applications involving the biology of the malignant cell,
as it relates to early (initiating) events in transformation. Emphasis is
on control of cell growth and death, and the molecular events in gene
regulation and protein modification and turnover that underlie this
control. Specific
areas covered by CAMP include: ·
Gene
regulation relevant to cancer, including chromatin structure and
remodeling, RNA stability, and translation. ·
Alterations in protein stability that are important
in the development of malignant phenotypes such as post-translational
modifications and abnormal degradation. ·
Signaling
transduction pathways related to oncogenesis. ·
Cell
cycle pathways and checkpoints that are altered in malignant
cells. ·
Cell
death pathways (both apoptotic and non-apoptotic) in cancer and the role
of caspases. ·
Cellular
immortalization and senescence pathways (including those mediated through
telomeres and telomerase). ·
Oncogenes
and tumor suppressor genes as they relate to the onset of
oncogenesis. CAMP has
the following shared interests within the ONC IRG: ·
With TCB: Applications focused on signal transduction
primarily related to cell cycle/checkpoints and/or apoptosis should be
assigned to CAMP. Other growth factor/signaling applications should
be assigned to TCB. ·
With CBSS relating to the development
of novel biomarkers, signatures, and patterns of tumors. If the
focus is on mechanisms, it should be assigned to CAMP. CAMP has
the following shared interests outside the ONC IRG: ·
With the Genes, Genomes and
Genetics [GGG] IRG: In general, studies of
normal regulatory processes would be assigned to GGG, whereas gene
regulation processes critical for transformation and/or tumor progression
would be assigned to CAMP. Studies that combine both normal
regulatory processes and processes critical for transformation and/or
tumor progression would be assigned to an IRG according to the main focus
of the research. ·
With the Cell Biology [CB]
IRG: In general, studies of normal cell biology processes would be
assigned to CB and processes of cell biology that are critical for
transformation and/or tumor progression would be assigned to CAMP.
Studies that combine both normal cell biological processes and processes
critical for transformation and/or tumor progression would be assigned to
an IRG according to the main focus of the research. ·
With the Organ-system
IRGs: In general, studies of normal cell biology
processes unique to a specific organ system would be assigned to the
appropriate organ-system IRG and studies of cell biology directed toward
understanding carcinogenesis would be assigned to CAMP. Tumor Cell Biology Study Section [TCB] The Tumor Cell Biology [TCB] Study Section reviews
applications focusing on signal transduction and growth factor regulation
of neoplastic transformation and progression. Specific
areas covered by TCB include: ·
Signaling
by cell surface receptors, growth factors, or cytokines, mediated by
protein kinases, phosphatases, or other processes. This includes the
analysis of the composition, formation, and functioning of signaling
complexes. ·
Analysis
of cross-talk among signaling pathways. ·
Pathways
regulated by oncogenes and tumor suppressor genes. How these genes
alter signaling in neoplasms and the consequences of these alterations on
tumor cell function. ·
Hormonal
modulation of carcinogenesis, including endocrine signaling as it relates
to tumorigenesis, steroid metabolism, and nuclear hormone
receptors. ·
Differentiation and transdifferentiation in
oncogenesis TCB has the
following shared interests within the ONC IRG: ·
With CAMP: Applications focused on signal transduction
primarily related to cell cycle/checkpoints, apoptosis, or initiating
events in oncogenic transformation should be assigned to CAMP. Other
growth factor/signaling applications should be assigned to TCB. ·
With TME: Applications focused on the effects of
extracellular actions of growth factors and other cytokines should be
assigned to TME; those focusing on intracellular signaling should be
assigned to TCB. ·
With CBSS relating to the development
of novel biomarkers, signatures, patterns and signaling pathways. If
related to diagnosis they should be assigned to CBSS; if related to
oncogenesis, they should be assigned to TCB. ·
With DT in studies of signal
transduction, cell cycle, and differentiation. If not closely
related to drug development, these studies should be assigned to
TCB. TCB has the
following shared interests outside the ONC IRG: ·
With the Genes, Genomes and
Genetics [GGG] IRG: In general, studies of
how genes alter signaling in normal cells and the consequences of those
alterations would be assigned to GGG; studies of how genes alter signaling
in neoplasms and the consequences of those alterations would be assigned
to TCB. Proposals that combine studies of gene alterations of
signaling in both normal and neoplastic cells would be assigned to an IRG
according to the main focus of the proposal. ·
With the Cell Biology [CB]
IRG: In general, studies of signaling in normal cells
would be assigned to CB; studies of signaling processes during neoplastic
transformation and progression would be assigned to TCB. Proposals
that combine studies of signaling in both normal cells and in neoplastic
cells would be assigned to an IRG according to the main focus of the
proposal. ·
With the Organ-system
IRGs: In general, studies of signaling processes
unique to cells in a specific organ system would be assigned to the
organ-system IRG; studies of signaling directed toward understanding
carcinogenesis would be assigned to TCB. ·
With the Endocrinology,
Metabolism, Nutrition and Reproductive Sciences [EMNR]
IRG: In general, studies of endometrial
hyperplasia; trophoblast neoplasia; germ cell tumors; pituitary adenomas;
as well as thyroid, parathyroid, and adrenal tumors would be assigned to
EMNR; studies of tumors in reproductive organs would be assigned to
TCB. In general, studies of obesity or insulin resistance as a risk
factor for cancer would be assigned to EMNR if the focus is on mechanisms
of metabolic fuel homeostasis or insulin action on cell growth; studies
focusing on the mechanism of oncogenesis would be assigned to TCB.
·
With the Digestive Sciences
[DIG] IRG: Studies of familial
adenomatous polyposis (FAP) as well as the pathology and treatment of
polyps in the GI system would be assigned to IRG 18. In general,
cell biological studies of GI, liver, or pancreatic cancers would be
assigned to TCB. Studies of Barrett's Esophagus would be assigned to
DIG or TCB depending on the focus of the study. ·
With the Brain Disorders and
Clinical Neuroscience [BDCN] IRG: In general, studies of tumor physiology and
pathology of the brain would be assigned to BDCN; studies for which a
brain tumors is being used as a model system would be assigned to TCB.
Tumor Microenvironment Study Section
[TME] The Tumor Microenvironment [TME] Study Section
reviews grant applications that deal with basic mechanisms of cancer cell
interactions with host systems including: immune, inflammatory, stromal,
vascular, and extracellular matrix. Emphasis is on evaluation of the
tumor as an organ-like structure with complex, dynamic cross-talk.
Included are studies of cell adhesion molecules, cell-cell interactions
and alterations of extracellular matrix. Studies of tumor
angiogenesis, involvement of tumor lymphatic components, and
organ-specific metastasis are assigned to this study section. Specific
areas covered by TME include: ·
Molecular
and cellular aspects of tumor cell biology (including gap junctions,
adherens, and tight junctions) and cross-talk with host cells (including
connective tissue cells, immune cells, inflammatory cells, and vascular
compartments). ·
Bi-directional interactions (feedback) during
neoplastic progression, angiogenesis and metastasis. ·
Cellular
and molecular aspects of epithelial-mesenchymal transition and
transactivation as it relates to tumor progression. ·
Development and exploration of physiologically
responsive organotypic models, and models of other tissue-like processes
such as angiogenesis, that allow investigation of tumor cells in the
context of a tissue-like environment. ·
Evaluation of cell-matrix adhesion and its dynamic
changes during tumor progression. Dynamics of cell-cell
communication for cell survival, growth, and invasion. Included are
studies of inter-cellular signaling and production of paracrine factors
(including TGF-beta) that regulate matrix formation and
remodeling. ·
Development and investigation of models for studying
organ-specific metastases, including crucial interactions between
metastatic cells and bone/bone marrow microenvironment or with other
site-specific organs. TME has the
following shared interests within the ONC IRG: ·
With TCB: Growth factors in the context of intracellular
signaling should be assigned to TCB; growth factor biology, as it affects
tumor progression and metastasis, should be assigned to TME. ·
With TCB: Activity of modulators of tumor cell adhesion,
shape, motility, and invasion as it pertains to intracellular signaling
pathways should be assigned to TCB, whereas applications dealing with
signals from cells and extracellular matrix should be assigned to TME.
·
With TPM: Studies that focus on the role of angiogenesis for
progression of tumors should be assigned to TPM; studies of angiogenesis,
as it relates to the tumor microenvironment, should be assigned to
TME. ·
With CBSS regarding "host factors"
such as immune signatures and vascular compartments. If the study
concerns development of diagnostic biomarkers it would be assigned to
CBSS, otherwise it would be assigned to TME. ·
With RTB regarding tumor
microenvironment: Studies of tumor microenvironment that relate to
radiation biology (e.g., hypoxia) should be assigned to RTB; other studies
of tumor microenvironment should be assigned to TME. TME has the
following shared interests outside the ONC IRG: ·
With the Hematology [HEME]
and Cardiovascular Sciences [CVS] IRGs: In general, studies of angiogenesis that are focused
on developmentally related processes or reactivation of embryonic
processes would be assigned to HEME or CVS; studies focused on tumor
angiogenesis would be assigned to TME. ·
With the Endocrinology,
Metabolism, Nutrition and Reproductive Sciences [EMNR]
IRG:
In general,
studies of the interaction of hormones with endocrine glands or
reproductive organs and their microenvironment would be assigned to EMNR;
studies of hormonal regulation of endocrine tumors would be assigned to
EMNR and hormonal regulation of other tumors to TME. ·
With the Musculoskeletal,
Oral, and Skin Sciences [MOSS] IRG: In general, studies of the interaction of
musculosketal, oral, skin, and bone cells with the tumor microenvironments
would be assigned to MOSS; studies focused on tumor cell- microenvironment
interactions would be assigned to TME. ·
With the Digestive Sciences
[DIG] IRG: In general, studies of the
interactions of pre-neoplastic cells of the GI, liver, or pancreas with
their microenvironments would be assigned to DIG; studies of the
interactions of tumor cells from GI, liver or pancreatic with their
microenvironment would be assigned to TME. Tumor Progression and Metastasis Study Section
[TPM] The TPM study section reviews grant applications that
deal with basic mechanisms of cancer progression and metastasis.
Special emphasis is placed on angiogenesis, hypoxia, invasion,
migration/motility and tumor cell extravasation, intravasation, survival,
adhesion and growth. Studies focusing on proteases, wound healing
and extracellular matrix remodeling, cell adhesion molecules/integrins
will also be assigned to this study section. These include in vitro and animal studies of
malignancies. Specific
areas covered by TPM: ·
Mechanisms and contributions of angiogenesis and
lymphoid components in both pre-malignant and malignant stages of tumor
progression (including the roles of hypoxia, angiogenic factors and their
receptors). ·
Studies
of tumor cell invasion, migration, and motility (including tumor cell
intravasation and extravasation). ·
Studies
on the basic biology of metastasis (including adhesion, growth, and
modification of the extracellular matrix environment). ·
Studies
of the role of proteases and remodeling of extracellular matrix as it
relates to tumor progression and metastasis. ·
Studies
of the mechanisms and roles of wound healing as they relate to tumor
progression. ·
The
contribution of cell membrane specializations (e.g., caveolae and lipid
rafts). ·
The role
of carbohydrate modifications as they relate to
invasion/progression. ·
Studies
of the role of steroid hormones and the mechanisms of hormone independence
in tumor progression. ·
Developmental processes related to tumor progression,
such as stem cell targets for organ-specific cancers. TPM has the
following shared interests within the ONC IRG: ·
With CE regarding signal
transduction, protein degradation, cell cycle checkpoint, apoptosis,
etc.: studies relating to causal processes of cancer should be
assigned to CE while those relating to transformation or progression
should be assigned to TPM. ·
With TME as it relates to
angiogenesis: studies focused on angiogenesis in tumor progression should
be assigned to TPM, while studies focused on the role of angiogenesis in
tumor progression in the context of the tumor microenvironment should be
assigned to TME. ·
With TME: Studies of proteolysis as it relates to cell-matrix
or cell-cell interactions should be assigned to TME; studies of
proteolysis as it affects tumor metastasis and invasion should be assigned
to TPM. ·
With CBSS in the discovery and
evaluation of markers for angiogenesis, invasion and other aspects of
cancer metastasis that may serve as clinical biomarkers: When the focus is
on identification of markers for clinical application, the study should be
assigned to CBSS; when the focus is on understanding the role of
metastasis, the study should be assigned to TPM. ·
With RTB, DMP, and
DT: studies of potential therapeutic agents targeting the
angiogenic pathway may be assigned to RTB, DMP, or DT. TPM has the
following shared interests outside the ONC IRG: ·
With the Biological Chemistry
and Macromolecular Biophysics [BCMB] and Cell Biology [CB]
IRGs: In general, studies of
extracellular matrix and proteolysis dealing with normal cell function
would be assigned to BCMB or CB; if they relate solely to neoplastic
progression they would be assigned to TPM. ·
With the Biology of
Development and Aging [BDA] IRG: In general, studies of developmental mechanisms and
processes would be assigned to BDA; studies directly related to tumor
metastasis would be assigned to TPM. ·
With the Hematology [HEME]
IRG: In general, studies of red blood cell
disorders/malignancies would be assigned to HEME; studies of lymphoma and
leukemia progression and metastasis would be assigned to TPM. ·
With the Cardiovascular
Sciences [CVS] IRG: In general, studies of
angiogenesis that are focused on developmentally related processes or
reactivation of embryonic processes would be assigned to CVS; studies
focused on tumor progression and metastasis would be assigned to
TPM. ·
With the Endocrinology,
Metabolism, Nutrition and Reproductive Sciences
[EMNR]
IRG: In general, studies of endometrial hyperplasia;
trophoblast neoplasia; germ cell tumors; pituitary adenomas; as well as
thyroid, parathyroid, and adrenal tumors would be assigned to EMNR;
studies of the role of hormones on the progression and metastasis of other
tumors and studies of tumors of reproductive organs would be assigned to
TPM. Studies of the relation between insulin/IGF signaling and tumor
progression and metastasis would be assigned to EMNR or to TPM depending
on the focus of the study. ·
With the Musculoskeletal,
Oral, and Skin Sciences [MOSS] IRG: In general, studies of the effect of musculoskeletal
tumors on the overall musculoskeletal system or which provide
understanding of the development of the musculoskeletal system would be
assigned to MOSS; studies of musculoskeletal, skin, and oral tumors and
metastasis would be assigned to TPM. ·
With the Brain Disorders and
Clinical Neuroscience [BDCN] IRG: In general, studies of CNS-unique physiological
factors on tumor progression and invasion would be assigned to BDCN;
studies of oncological mechanisms on the progression and invasion of CNS
tumors would be assigned to TPM. Chemo/Dietary Prevention Study Section
[CDP] The Chemo/Dietary Prevention Study Section reviews
grant applications that address nutrition, dietary and chemopreventive
factors and their use in intervention for modulation of cancer risk, and
inhibition of cancer progression. This study section reviews grant
applications dealing with basic mechanistic studies, preclinical and
clinical (phase-1 and phase-2) studies as well as discovery,
evaluation, and validation of biomarkers. Specific
areas covered by CDP include: ·
Discovery
and evaluation of diets as well as individual dietary factors,
chemopreventive agents, and targets for the modulation of
cancer. ·
Mechanisms of cancer modulation by chemical and
nutritional factors studied at the biochemical, molecular, and cellular
levels. ·
Preclinical prevention studies (including in vitro and in vivo
evaluation of efficacy and safety). ·
Phase-1
and Phase-2 clinical trials of chemopreventive agents. ·
Development and validation of markers important in
prevention, including markers of cancer risk and progression. ·
Design,
development,
and synthesis of preventive agents. ·
Design
and development of approaches to the prevention of tumors via other
factors, such as exercise or vaccines. ·
Diet
restriction, antioxidant defense mechanisms, DNA methylation, traditional
(e.g., arytenoids, selenium, vitamins) and other food
components. ·
In vitro and in vivo
pharmacokinetic and pharmacodynamic studies of chemopreventive
agents. ·
Effect of
dietary factors on hormonal carcinogenesis, chemical carcinogenesis,
differentiation/transdifferentiation, apoptosis, and oxidative
stress CDP has the
following shared interests within the ONC IRG: ·
With CE in studies of mechanisms of
cancer initiation: When the emphasis is on cancer prevention, the
application should be assigned to CDP. ·
With CG in the role of gene
polymorphisms: When the emphasis is on cancer prevention, the
application should be assigned to CDP. ·
With TCB in studies of biological
markers of cancer and mechanisms of tumor progression: When the
emphasis is on cancer prevention, the application should be assigned to
CDP. ·
With CBSS in proposals to discover, or
validate biomarkers for cancer: When the emphasis is on cancer
prevention, the application should be assigned to CDP. ·
With CII in applications dealing with
cancer vaccines and immunological agents: When the emphasis is on
cancer prevention, the application should be assigned to CDP. ·
With DMP in applications proposing
synthesis, isolation, evaluation and validation of new drugs: When
the emphasis is on cancer prevention, the application should be assigned
to CDP. ·
With CONC in applications proposing
phase I and II trials and in the development of chemopreventive
drugs: When the emphasis is on cancer prevention, the application
may be assigned to CDP. CDP has the
following shared interests outside the ONC IRG: ·
With the Biological Chemistry
and Macromolecular Biophysics [BCMB] IRG: In general, research on the chemistry and
synthesis of new agents/drugs would be assigned to BCMB; when the emphasis
is on cancer prevention, the application would be assigned to
CDP. ·
With the Health of the
Population [HOP] IRG: HOP reviews applications
dealing with cancer prevention that involve a community-based approach,
(e.g., use of mass media to increase use of sunscreen, culturally tailored
approaches to increase screening compliance). ·
With the Risk, Prevention and
Health Behavior [RPHB] IRG: Studies of human behaviors
that relate to cancer risk and the development of behavioral approaches to
cancer prevention would be assigned to RPHB. ·
With organ-specific
IRGs
that deal with health and disease of particular organs/tissues: In
general, when the emphasis is on cancer prevention, the application would
be assigned to CDP. ·
With the Endocrinology,
Metabolism, Nutrition and Reproductive Sciences [EMNR]
IRG: Studies focusing on insulin resistance or
obesity as a risk factor for cancer should be assigned to EMNR.
|